Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.81
9.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
Revenue
Aurinia Pharmaceuticals Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Revenue
$220.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
269%
|
CAGR 10-Years
73%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Revenue
CA$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Revenue
$84.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
33%
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Revenue
$51.1m
|
CAGR 3-Years
700%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Covalon Technologies Ltd
XTSX:COV
|
Revenue
CA$29.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
12%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Revenue
CA$2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-4%
|
|
Aurinia Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Aurinia Pharmaceuticals Inc
|
Total Revenue:
175.5m
USD
|
|
United States:
158m
USD
|
|
Japan:
17.6m
USD
|
Breakdown by Segments
Aurinia Pharmaceuticals Inc
|
Total Revenue:
175.5m
USD
|
|
Product Revenue, Net:
158.5m
USD
|
|
License, Collaboration And Royalty Revenue:
17m
USD
|
Aurinia Pharmaceuticals Inc
Glance View
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia and currently employs 300 full-time employees. The company went IPO on 2001-07-16. The firm is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The firm has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The company also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.
See Also
What is Aurinia Pharmaceuticals Inc's Revenue?
Revenue
220.4m
USD
Based on the financial report for Sep 30, 2024, Aurinia Pharmaceuticals Inc's Revenue amounts to 220.4m USD.
What is Aurinia Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
73%
Over the last year, the Revenue growth was 39%. The average annual Revenue growth rates for Aurinia Pharmaceuticals Inc have been 45% over the past three years , 269% over the past five years , and 73% over the past ten years .
You don't have any saved screeners yet
